HOUSE_OVERSIGHT_024053.jpg
2 MB
Extraction Summary
1
People
5
Organizations
0
Locations
0
Events
2
Relationships
3
Quotes
Document Information
Type:
Investment strategy memorandum / confidential offering document
File Size:
2 MB
Summary
This document is page 42 of a confidential investment strategy memorandum for NLV-III (New Leaf Ventures III). It details the strategy for investing in 'Biological Research Tools & Infrastructure,' highlighting the benefits of lower regulatory risks compared to biopharma and aiming for companies near the commercial stage. The document notes that up to 15% of the fund will be allocated to this sector and medical devices, citing 'Advanced Cellular Diagnostics' from the previous NLV-II fund as a successful example.
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Investment Managers |
Managers of NLV-III who expect investments in this sector to comprise up to 15% of the fund.
|
Organizations (5)
| Name | Type | Context |
|---|---|---|
| NLV-III |
The investment fund (New Leaf Ventures III) whose strategy is being detailed.
|
|
| New Leaf |
The venture capital firm managing the portfolios.
|
|
| Advanced Cellular Diagnostics |
Cited as an example company in the New Leaf portfolio (NLV-II).
|
|
| NLV-II |
The previous fund containing Advanced Cellular Diagnostics.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024053'.
|
Relationships (2)
An example of a tools company in the New Leaf portfolio is Advanced Cellular Diagnostics (NLV-II, commercial stage).
Key Quotes (3)
"NLV-III’s investment strategy in Biological Research Tools and Infrastructure will focus on identifying companies that are at or near the commercial stage with novel products targeting established, high growth markets -- such as DNA sequencing and personalized medicine."Source
HOUSE_OVERSIGHT_024053.jpg
Quote #1
"Unlike biopharmaceutical or medical device product development, these new reagents are not subject to the risks of costly clinical trials, regulatory approvals and payer reimbursement."Source
HOUSE_OVERSIGHT_024053.jpg
Quote #2
"The Fund Managers expect investments in this sector and the medical device sector to comprise up to 15% of the Fund."Source
HOUSE_OVERSIGHT_024053.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document